Estrogen priming in advanced breast cancer

M. Maghsoodnia, W. M. Holleran, M. W. DeGregorio

Research output: Contribution to journalArticle

Abstract

The successful treatment of advanced breast cancer has reached a plateau in recent years. Estrogen priming is a new combination therapy involving estrogens, antiestrogens, and chemotherapy that may result in the improvement of treatment responses. This investigational therapy is designed to synchronize cell cycles with estrogens and antiestrogens in order to enhance the activity of cell cycle-specific anticancer drugs. The pharmacological manipulation of cell growth coupled with appropriate antineoplastic agents could result in a new treatment approach for advanced breast cancer. The rational and current status of estrogen priming are reviewed.

Original languageEnglish (US)
Pages (from-to)672-675
Number of pages4
JournalDrug Intelligence and Clinical Pharmacy
Volume22
Issue number9
StatePublished - 1988
Externally publishedYes

Fingerprint

Estrogens
Breast Neoplasms
Estrogen Receptor Modulators
Cell Cycle
Activity Cycles
Investigational Therapies
Therapeutics
Antineoplastic Agents
Pharmacology
Drug Therapy
Growth
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Maghsoodnia, M., Holleran, W. M., & DeGregorio, M. W. (1988). Estrogen priming in advanced breast cancer. Drug Intelligence and Clinical Pharmacy, 22(9), 672-675.

Estrogen priming in advanced breast cancer. / Maghsoodnia, M.; Holleran, W. M.; DeGregorio, M. W.

In: Drug Intelligence and Clinical Pharmacy, Vol. 22, No. 9, 1988, p. 672-675.

Research output: Contribution to journalArticle

Maghsoodnia, M, Holleran, WM & DeGregorio, MW 1988, 'Estrogen priming in advanced breast cancer', Drug Intelligence and Clinical Pharmacy, vol. 22, no. 9, pp. 672-675.
Maghsoodnia M, Holleran WM, DeGregorio MW. Estrogen priming in advanced breast cancer. Drug Intelligence and Clinical Pharmacy. 1988;22(9):672-675.
Maghsoodnia, M. ; Holleran, W. M. ; DeGregorio, M. W. / Estrogen priming in advanced breast cancer. In: Drug Intelligence and Clinical Pharmacy. 1988 ; Vol. 22, No. 9. pp. 672-675.
@article{5ac6a0561b84425b89ae83d0106db4af,
title = "Estrogen priming in advanced breast cancer",
abstract = "The successful treatment of advanced breast cancer has reached a plateau in recent years. Estrogen priming is a new combination therapy involving estrogens, antiestrogens, and chemotherapy that may result in the improvement of treatment responses. This investigational therapy is designed to synchronize cell cycles with estrogens and antiestrogens in order to enhance the activity of cell cycle-specific anticancer drugs. The pharmacological manipulation of cell growth coupled with appropriate antineoplastic agents could result in a new treatment approach for advanced breast cancer. The rational and current status of estrogen priming are reviewed.",
author = "M. Maghsoodnia and Holleran, {W. M.} and DeGregorio, {M. W.}",
year = "1988",
language = "English (US)",
volume = "22",
pages = "672--675",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "9",

}

TY - JOUR

T1 - Estrogen priming in advanced breast cancer

AU - Maghsoodnia, M.

AU - Holleran, W. M.

AU - DeGregorio, M. W.

PY - 1988

Y1 - 1988

N2 - The successful treatment of advanced breast cancer has reached a plateau in recent years. Estrogen priming is a new combination therapy involving estrogens, antiestrogens, and chemotherapy that may result in the improvement of treatment responses. This investigational therapy is designed to synchronize cell cycles with estrogens and antiestrogens in order to enhance the activity of cell cycle-specific anticancer drugs. The pharmacological manipulation of cell growth coupled with appropriate antineoplastic agents could result in a new treatment approach for advanced breast cancer. The rational and current status of estrogen priming are reviewed.

AB - The successful treatment of advanced breast cancer has reached a plateau in recent years. Estrogen priming is a new combination therapy involving estrogens, antiestrogens, and chemotherapy that may result in the improvement of treatment responses. This investigational therapy is designed to synchronize cell cycles with estrogens and antiestrogens in order to enhance the activity of cell cycle-specific anticancer drugs. The pharmacological manipulation of cell growth coupled with appropriate antineoplastic agents could result in a new treatment approach for advanced breast cancer. The rational and current status of estrogen priming are reviewed.

UR - http://www.scopus.com/inward/record.url?scp=0023786288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023786288&partnerID=8YFLogxK

M3 - Article

C2 - 3063478

AN - SCOPUS:0023786288

VL - 22

SP - 672

EP - 675

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 9

ER -